-
公开(公告)号:US20110118245A1
公开(公告)日:2011-05-19
申请号:US12933402
申请日:2009-03-17
申请人: Sunny Abraham , Shripad S. Bhagwat , Brian T. Campbell , Qi Chao , Raffaella Faraoni , Mark W. Holladay , Andiliy G. Lai , Martin W. Rowbottom , Eduardo Setti , Kelly G. Sprankle
发明人: Sunny Abraham , Shripad S. Bhagwat , Brian T. Campbell , Qi Chao , Raffaella Faraoni , Mark W. Holladay , Andiliy G. Lai , Martin W. Rowbottom , Eduardo Setti , Kelly G. Sprankle
IPC分类号: A61K31/517 , C07D413/12 , C07D491/056 , A61K31/519 , C07D413/14 , A61K31/5377 , C07D417/14 , A61K31/541 , C07D403/12 , C07D239/88 , C07D401/12 , A61P19/10 , A61P29/00 , A61P3/10 , A61P1/00 , A61P19/02 , A61P37/00 , A61P35/04
CPC分类号: C07D239/88 , A61K9/20 , A61K9/48 , A61K31/517 , A61K45/06 , C07D239/93 , C07D261/14 , C07D413/12
摘要: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
摘要翻译: 提供根据式(I)的化合物,组合物和方法用于调节RAF激酶(包括BRAF激酶)的活性,并用于治疗,预防或改善由RAF激酶介导的疾病或病症的一种或多种症状。 式(I):或其药学上可接受的盐,溶剂合物,其水合物的包合物,其中X为O或S(O)t; Ra是O或S.
-
公开(公告)号:US08618289B2
公开(公告)日:2013-12-31
申请号:US12933402
申请日:2009-03-17
申请人: Sunny Abraham , Shripad S. Bhagwat , Brian T. Campbell , Qi Chao , Raffaella Faraoni , Mark W. Holladay , Andiliy G. Lai , Martin W. Rowbottom , Eduardo Setti , Kelly G. Sprankle
发明人: Sunny Abraham , Shripad S. Bhagwat , Brian T. Campbell , Qi Chao , Raffaella Faraoni , Mark W. Holladay , Andiliy G. Lai , Martin W. Rowbottom , Eduardo Setti , Kelly G. Sprankle
IPC分类号: C07D239/70 , A01N43/54
CPC分类号: C07D239/88 , A61K9/20 , A61K9/48 , A61K31/517 , A61K45/06 , C07D239/93 , C07D261/14 , C07D413/12
摘要: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
摘要翻译: 提供根据式(I)的化合物,组合物和方法用于调节RAF激酶(包括BRAF激酶)的活性,并用于治疗,预防或改善由RAF激酶介导的疾病或病症的一种或多种症状。 式(I):或其药学上可接受的盐,溶剂合物,其水合物的包合物,其中X为O或S(O)t; Ra是O或S.
-
公开(公告)号:US08349851B2
公开(公告)日:2013-01-08
申请号:US12714323
申请日:2010-02-26
申请人: Sunny Abraham , Qi Chao , Michael J. Hadd , Mark W. Holladay , Gang Liu , Eduardo Setti
发明人: Sunny Abraham , Qi Chao , Michael J. Hadd , Mark W. Holladay , Gang Liu , Eduardo Setti
IPC分类号: A61K31/517
CPC分类号: A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/12 , C07D405/14
摘要: Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
-
公开(公告)号:US20100317659A1
公开(公告)日:2010-12-16
申请号:US12714323
申请日:2010-02-26
申请人: Sunny Abraham , Qi Chao , Michael J. Hadd , Mark W. Holladay , Gang Liu , Eduardo Setti
发明人: Sunny Abraham , Qi Chao , Michael J. Hadd , Mark W. Holladay , Gang Liu , Eduardo Setti
IPC分类号: A61K31/5377 , C07D403/12 , C07D413/14 , C07D407/14 , A61K31/517 , A61P35/00 , A61P37/00 , A61P29/00 , A61P37/06 , A61P37/02
CPC分类号: A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/12 , C07D405/14
摘要: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
摘要翻译: 本文提供了用于治疗JAK激酶介导的疾病的喹唑啉化合物,包括JAK2激酶,JAK3激酶或TYK2激酶介导的疾病。 还提供了包含该化合物的药物组合物和使用该化合物和组合物的方法。
-
公开(公告)号:US20110269740A1
公开(公告)日:2011-11-03
申请号:US13000606
申请日:2009-07-02
申请人: Sunny Abraham , Qi Chao , Michael Hadd , Mark Holladay , Gang Liu , Mitchell Nambu , Eduardo Setti
发明人: Sunny Abraham , Qi Chao , Michael Hadd , Mark Holladay , Gang Liu , Mitchell Nambu , Eduardo Setti
IPC分类号: A61K31/53 , A61K31/5377 , A61P35/00 , A61P19/02 , A61P37/06 , A61P17/02 , A61P3/10 , C07D487/04 , A61P29/00
CPC分类号: C07D487/04
摘要: Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
摘要翻译: 本文提供了用于治疗JAK激酶的吡咯并三嗪化合物,包括JAK2激酶介导的疾病。 还提供了包含该化合物的药物组合物和使用该化合物和组合物的方法。
-
公开(公告)号:US20130035326A1
公开(公告)日:2013-02-07
申请号:US13390911
申请日:2010-08-18
申请人: Sunny Abraham , Mark W. Holladay , Gang Liu , Shimin Xu
发明人: Sunny Abraham , Mark W. Holladay , Gang Liu , Shimin Xu
IPC分类号: C07D413/12 , C07D498/04 , A61K31/5383 , A61K31/4375 , C07D471/04 , C07D413/14 , A61K31/444 , A61K31/553 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/505 , C07D401/12 , A61K31/497 , A61K31/437 , A61K31/5513 , C07D239/42 , C07D401/04 , A61P29/00 , A61P37/00 , A61P35/00 , A61P35/02 , A61P37/06 , A61P17/02 , A61P13/12 , A61P17/06 , A61P37/08 , A61P11/00 , A61P19/02 , A61P25/00 , A61P19/10 , A61P11/06 , A61P37/02 , A61P31/00 , A61P3/10 , A61P1/00 , A61P1/04 , A61P19/04 , A61K31/4439
CPC分类号: C07D239/42 , A61K31/4353 , A61K31/4375 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/5375 , A61K31/5377 , A61K31/553 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D498/04
摘要: Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
摘要翻译: 本文提供了用于治疗KIT,CSF-1R和/或FLT3激酶介导的疾病的化合物。 还提供了包含该化合物的药物组合物和使用该化合物和组合物的方法。
-
-
-
-
-